This table lists all the major pharma collaborations, acquisitions and mergers agreed during October 2013.
For an indepth analysis of these deals, read ‘Pharma deals during October 2013’
|
Licensor acquired / licensee acquirer |
Deal type |
Product / technology |
Headline ($m) |
| Celesio / McKesson | Acquisition | Wholesaler and pharmacy chains | 8,300 |
| Mitokyne / Astellas | R&D collaboration and option to acquire | Molecules targeting mitochondrial function to treat genetic, metabolic or neurodegenerative disorders (discovery) | 730 |
| Spirogen / MedImmune | Acquisition | ADC technology – oncology (lead asset in phase II) | 440 |
| Acino / Avista Capital and Nordic Capital | Acquisition | Portfolio of drug delivery products (marketed) | 439 |
| Sideris Pharmaceuticals / Novartis | Option to acquire | Iron chelator SP-420 for transfusional iron overload (preclinical) | 300 |
| *Vivus / Auxilium | Commercialisation | Stendra (avanafil) for erectile dysfunction (approved) | 300 |
| **Epirus / Orygen Biotecnologia | Development, manufacture and commercialisation | Multiple biosimilars including BOW015 (Remicade biosimilar) (phase III) | 275 |
| Depomed / PDL Pharma | Royalty and milestone monetisation | Licence agreements in the type 2 diabetes therapeutic area | 240.5 |
| ImmunoGen / Novartis | Licence | ADC technology – extension of 2010 agreement | 200 |
| ‡Xention / Servier | Development and commercialisation, option to acquire IP after 2 x p2 studies | XEN-D103 ion channel modulator for atrial fibrillation (phase I) | 162.4 |
| Anacor / Valeant | Settlement | Settlement agreement for breach of contract dispute | 143 |
| ‡‡ Stallergenes / Greer Labs | Commercialisation | Oralair, grass allergy sublingual tablet (pre-registration) | 120 |
| Osiris Therapeutics / Mesoblast | Asset acquisition | Mesenchymal stem cell business, including Prochymal (approved) | 100 |
| †Hutchison MediPharma / Eli Lilly | Licence, co-development and commercialisation | ruquintinib VEGF inhibitor for solid tumours (phase II) | 86.5 |
| PharmAkea / Celgene | Strategic three year collaboration, option to acquire company | Discovery platform for small molecules for cancer and fibrotic disease | 35 |
| Moderna Therapeutics / DARPA | R&D grant | mRNA therapeutics for biodefence targets (discovery) | 25 |
| ††Ablynx / Eddingpharm | Licence | Anti-RANKL Nanobody, ALX-0141 for osteoporosis and bone metastases (preclinical) | 2.7 upfront |
All deals are worldwide unless otherwise noted – see below:
* US and Canada
** Brazil
‡ Excluding US and Japan
‡‡ US
† China
†† China, Hong Kong, Macao and Taiwan
ADC = antibody drug conjugate
VEGF = Vascular Endothelial Growth Factor
DARPA = Defense Advanced Research Projects Agency